Kancera co-founder and scientific adviser Professor Håkan Mellstedt has demonstrated a sustained presence of Kancera's ROR1 target over time in patients with non-progressive disease and also a significant increase of this putative tumor target in patients with progressive stages...
Read MoreJanuary 1 - September 30, 2011 All figures relate to the Kancera Group unless otherwise specified. Kancera's acquisition of iNovacia AB was completed on February 17, 2011 and iNovacia AB's operations are therefore included in the financial statements with...
Read MoreAktieägarna i Kancera AB (publ) kallas härmed till extra bolagsstämma torsdagen den 10 november 2011 kl. 16.00 på Kilpatrick Townsend Advokatbyrås kontor, Hovslagargatan 5B, 5 tr i Stockholm.
Read MoreiNovacia, an internationally established contract research company owned by Kancera AB (Nasdaq OMX Stockholm First North, KAN), announces today that highly potent inhibitors of a target protein in the parasite Schistosoma have been developed. This parasite infects annually...
Read MoreKancera reports that the company has registered an international patent application (PCT/EP2011/066250) for a new class of compounds targeting the energy metabolism of cancer cells. This new class of synthetic molecules inhibits the target protein PFKFB3. Inhibition of this...
Read MoreKancera has in collaboration with scientists at the Karolinska Institute identified active compounds that effectively kill pancreatic cancer cells. Annually over 100 000 people are diagnosed with pancreatic cancer in Europe and the US. Ratio of survival, five years...
Read MoreJanuary 1 - June 30, 2011 All figures relate to the Kancera Group unless otherwise specified. Kancera's acquisition of iNovacia AB was completed on February 17, 2011 and iNovacia AB's operations are therefore included in the financial statements with...
Read MoreKancera is announcing today that the company has raised SEK 7.6m before issue costs in a rights issue. The capital raised will be used to further develop the company's ROR technology to attack solid tumors.
Read MoreAt a cancer seminar in Båstad tomorrow, July 7, Professor Håkan Mellstedt will present the basis for further development of Kancera's ROR technology for the purpose of attacking solid tumors that are hard to treat. Kancera has already reported...
Read MoreiNovacia, the drug discovery service provider and subsidiary of Kancera AB (Nasdaq OMX Stockholm First North, KAN), today announced the addition of over 20,000 novel compounds to its small-molecule screening collection. This is in line with the continuous development...
Read More